Mesothelioma Treatment
Mesothelioma Cancer
- Causes of Mesothelioma
- Mesothelioma Symptoms
- Mesothelioma Diagnosis
- Mesothelioma Stages
- Mesothelioma Treatment
- Innovative Mesothelioma Treatments
- Managing Mesothelioma Pain
- Nutrition Information for Mesothelioma Patients
- Specialized Mesothelioma Care
- Mesothelioma Risks
- Mesothelioma Support Groups
- Find a Mesothelioma Attorney
- Mesothelioma News
Mesothelioma Directory
Immunotoxin Therapy, Pemetrexed, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed by Surgery
Get Help Today
Looking for help or additional information? Contact us today.| Conditions: | Malignant Mesothelioma |
| Start Date: | June 1, 2007 |
| Phase: | Phase I |
| Status: | Recruiting |
| NCT ID: | NCT00575770 |
| Study Type: | Interventional |
| Intervention: | Biological: SS1(dsFv)-PE38 immunotoxin|Drug: cisplatin|Drug: pemetrexed disodium|Other: immunoenzyme technique|Other: immunohistochemistry staining method|Other: pharmacological study|Procedure: quality-of-life assessment |
| Study Design: | Allocation: Non-Randomized|Control: Active Control|Masking: Open Label|Primary Purpose: Treatment |
| Results: | No Results Available |
| Sponsors: | National Cancer Institute (NCI) |
| Ages: | Adult|Senior |
| Enrollment: | 24 |
| Funded By: | NIH |
| First Received: | December 15, 2007 |
| End Date: | |
| Last Updated: | November 26, 2009 |
| Last Verified: | March 1, 2008 |